also confirmed that AML patients in CR before transplant and with a median expression of WT1 >100/104 ABL after transplant had a higher relapse risk (53% vs 26%) and a lower 5-year survival (36% vs 62%) when compared with patients who had less than this cutoff (14). This evidence concerns the gene WT1 and acute myeloid leukemia.